Abeona Therapeutics Inc (ABEO) Expected to Announce Earnings of -$0.23 Per Share

Equities analysts forecast that Abeona Therapeutics Inc (NASDAQ:ABEO) will post ($0.23) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Abeona Therapeutics’ earnings, with estimates ranging from ($0.26) to ($0.19). Abeona Therapeutics posted earnings of ($0.13) per share during the same quarter last year, which suggests a negative year over year growth rate of 76.9%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 21st.

On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.97) to ($0.74). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.81) per share, with EPS estimates ranging from ($1.13) to ($0.34). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. The business had revenue of $0.82 million during the quarter, compared to analysts’ expectations of $1.81 million.

Several research firms have recently commented on ABEO. BidaskClub raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, June 28th. B. Riley began coverage on shares of Abeona Therapeutics in a research note on Wednesday, June 27th. They issued a “buy” rating and a $26.00 price objective for the company. TheStreet lowered shares of Abeona Therapeutics from a “c-” rating to a “d+” rating in a research note on Wednesday, August 29th. ValuEngine lowered shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, September 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Abeona Therapeutics has a consensus rating of “Buy” and an average price target of $26.80.

A number of institutional investors have recently modified their holdings of ABEO. Fortaleza Asset Management Inc. purchased a new position in Abeona Therapeutics in the second quarter worth approximately $104,000. Parkside Advisors LLC purchased a new position in Abeona Therapeutics in the third quarter worth approximately $160,000. United Services Automobile Association purchased a new position in Abeona Therapeutics in the second quarter worth approximately $162,000. Sabby Management LLC purchased a new position in Abeona Therapeutics in the first quarter worth approximately $187,000. Finally, MetLife Investment Advisors LLC lifted its stake in Abeona Therapeutics by 57.8% in the second quarter. MetLife Investment Advisors LLC now owns 19,333 shares of the biopharmaceutical company’s stock worth $309,000 after acquiring an additional 7,085 shares during the last quarter. Institutional investors own 76.24% of the company’s stock.

Shares of NASDAQ ABEO traded up $0.37 during midday trading on Monday, hitting $10.40. The company’s stock had a trading volume of 629,959 shares, compared to its average volume of 886,407. Abeona Therapeutics has a 1 year low of $9.66 and a 1 year high of $22.00. The firm has a market cap of $613.67 million, a price-to-earnings ratio of -15.76 and a beta of 1.10.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Read More: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply